Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Aleshin

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2021
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of RecurrencesTenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Gynecologic Oncology|September 18, 2022
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancerJune Y Hou, Jocelyn S Chapman, Ekaterina Kalashnikova, et al.
JCO Precision Oncology|July 30, 2021
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesFotios Loupakis, Shruti Sharma, Madiha Derouazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic ImplicationsTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Journal of the American Academy of Dermatology|October 12, 2025
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient managementTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2021
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of RecurrencesTenna Vesterman Henriksen, Noelia Tarazona, Amanda Frydendahl, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Gynecologic Oncology|September 18, 2022
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancerJune Y Hou, Jocelyn S Chapman, Ekaterina Kalashnikova, et al.
JCO Precision Oncology|July 30, 2021
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesFotios Loupakis, Shruti Sharma, Madiha Derouazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic ImplicationsTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Journal of the American Academy of Dermatology|October 12, 2025
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient managementTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Pageof 7